From professional translators, enterprises, web pages and freely available translation repositories.
studie fvf2587g (anchor)
study fvf2587g (anchor)
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
studie fvf2587g (anchor) 15 +10, 7 10 (bokstäver)
study fvf2587g (anchor) 15 mean change in visual acuity ± se
Last Update: 2011-10-23
Usage Frequency: 1
Quality:
anchor lucentis 0, 5 mg (n=140) verteporfin pdt (n=143)
anchor lucentis 0.5 mg (n=140) verteporfin pdt (n=143)
Last Update: 2011-10-23
Usage Frequency: 1
Quality:
i studie fvf2587g (anchor) fick patienter med företrädesvis klassiska lesioner med cnv antingen:
in study fvf2587g (anchor), patients with predominantly classic cnv lesions received either:
Last Update: 2012-04-11
Usage Frequency: 2
Quality:
man observerade statistiskt signifikanta patientrapporterade visuella funktionsförbättringar med ranibizumabbehandling i både marina och anchor jämfört med kontrollgruppen, enligt mätningar med nei vfq-25.
statistically significant patient-reported visual functioning benefits were observed in both marina and anchor with ranibizumab treatment over the control group as measured by the nei vfq-25.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
medelförändring av synskärpan från baslinjen till månad 24 i studie fvf2598g (marina) och studie fvf2587g (anchor)
mean change in visual acuity from baseline to month 24 in study fvf2598g (marina) and study fvf2587g (anchor)
Last Update: 2012-04-11
Usage Frequency: 2
Quality:
figur 1 medelförändring av synskärpan från baslinjen till månad 24 i studie fvf2598g (marina) och studie fvf2587g (anchor)
figure 1 mean change in visual acuity from baseline to month 24 in study fvf2598g (marina) and study fvf2587g (anchor)
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
cursor document. anchor (int rad, int kolumn, char tecken); cursor document. anchor (cursor markör, char tecken);
cursor document. anchor( int line, int column, char character); cursor document. anchor( cursor cursor, char character);
Last Update: 2011-10-23
Usage Frequency: 1
Quality:
4 de biverkningar som anges nedan uppkom med en högre frekvens (minst 2 procentenheter) hos patienter som behandlades med lucentis 0, 5 mg än hos de som fick kontrollbehandling (simulerad injektion eller pdt med verteporfin) i de tre kontrollerade fas iii- studierna fvf2598g (marina), fvf2587g (anchor) och fvf3192g (pier).
the adverse events listed below occurred at a higher rate (at least 2 percentage points) in patients receiving treatment with lucentis 0.5 mg than in those receiving control treatment (sham or verteporfin pdt) in the three controlled phase iii studies fvf2598g (marina), fvf2587g
Last Update: 2011-10-23
Usage Frequency: 1
Quality:
